ASCA Testing Versus Traditional Testing for Devices

A medical device test report is more than evidence that a product passed a protocol. For a submission team, it is part of the regulatory record that supports safety, performance, and the credibility of the manufacturer’s verification process. That is why ASCA testing versus traditional testing is a meaningful planning decision, particularly when an FDA premarket submission will rely on consensus standards and laboratory-generated data.

The distinction does not mean that traditional testing is inherently inadequate. A qualified laboratory can perform high-quality standards-based testing outside the FDA’s Accreditation Scheme for Conformity Assessment program. The difference is the formal relationship among the laboratory, its accredited scope, the applicable FDA-recognized consensus standard, and the FDA’s review process. Understanding that relationship early helps manufacturers select the correct test path, avoid scope mismatches, and prepare documentation that is fit for its intended regulatory use.

What FDA ASCA Testing Is Designed to Do

FDA’s ASCA program is intended to increase confidence in conformity assessment for certain medical device standards. Under the program, testing laboratories may be accredited for specific test methods associated with eligible FDA-recognized consensus standards. An ASCA-accredited laboratory conducts testing within its approved scope and issues an ASCA test report using the program’s specified reporting approach.

For device manufacturers, the practical value is regulatory clarity. When an ASCA test report is appropriately prepared for an eligible standard and device application, FDA generally intends to rely on the results without requesting the underlying test data during premarket review. This can reduce avoidable questions about laboratory competence, method execution, or whether the reported results adequately support a declaration of conformity.

That benefit has boundaries. ASCA status does not replace a manufacturer’s responsibility to establish design controls, risk management, clinical evidence where applicable, or a complete device-specific regulatory strategy. It also does not make a device automatically compliant or cleared. The test method, standard version, laboratory scope, device configuration, and submission context must all align.

ASCA Testing Versus Traditional Testing: The Core Difference

Traditional testing generally refers to standards-based evaluation performed outside the ASCA reporting framework. The laboratory may be accredited to ISO/IEC 17025, may have extensive medical device expertise, and may generate technically sound data and reports. Those reports can support product development, verification, risk assessment, supplier qualification, international market access, and FDA submissions.

The central difference is not the scientific discipline applied to the test. It is the FDA-recognized conformity assessment pathway attached to the work. ASCA testing is performed by an FDA ASCA-accredited laboratory, within the laboratory’s authorized ASCA scope, according to an eligible standard and specified program requirements. Traditional testing may be equally rigorous but does not carry the same ASCA program designation.

For an FDA reviewer, an ASCA report can provide a more defined basis for relying on the laboratory’s conformity assessment. For a traditional report, FDA may accept the evidence as submitted, request clarification, or request supporting information such as test protocols, raw data, deviations, accreditation records, equipment details, or justification for the selected methods. The level of follow-up depends on the device, standard, report quality, and the questions raised by the submission.

Accreditation Scope Matters More Than a Laboratory Label

A common planning error is to treat a laboratory’s general accreditation as interchangeable with ASCA eligibility. ISO/IEC 17025 accreditation and FDA ASCA accreditation are related but distinct. ISO/IEC 17025 addresses the competence of testing and calibration laboratories under a defined scope. FDA ASCA recognition applies to specified standards and test methods within an ASCA-accredited laboratory’s approved scope.

Before commissioning testing, regulatory and engineering teams should verify several points: the exact standard and edition needed for the submission, whether that standard is currently eligible under the ASCA program, whether the intended laboratory is ASCA-accredited for the applicable test method, and whether the device and configuration fall within the practical limits of the laboratory’s capabilities.

This review is especially relevant for complex systems. An ultrasound device may require electrical safety and essential performance testing, acoustic output measurements, image quality evaluation, software documentation, usability engineering evidence, and electromagnetic compatibility assessment. A laboratory may be well suited to one or more of these evaluations without holding ASCA scope for every applicable standard. The appropriate strategy may therefore combine ASCA testing for eligible portions of the verification plan with traditional testing for specialized or non-ASCA work.

When ASCA Testing May Be the Better Regulatory Choice

ASCA testing is often most useful when a manufacturer intends to support an FDA premarket submission with conformity to an eligible FDA-recognized consensus standard. It can be particularly valuable when the test results address foundational safety or performance requirements and the project timeline would be affected by extended FDA questions about the test laboratory or documentation.

The program can also strengthen planning discipline. Because ASCA work requires close alignment with scope and reporting requirements, teams are encouraged to resolve standard selection, device configuration, acceptance criteria, and deviations before testing begins. That reduces the risk of completing a test program only to find that an outdated standard edition, incomplete configuration, or undocumented modification limits its regulatory usefulness.

ASCA may not be the preferred route in every case. If the required standard is not eligible, the test method is outside an accredited ASCA scope, or the project concerns exploratory development work rather than submission-ready evidence, traditional testing may be more appropriate. The best choice depends on the intended use of the data, not on a simple assumption that one report format is universally superior.

Where Traditional Testing Remains Essential

Traditional testing remains central to medical device development and compliance. Manufacturers need data well before a final submission package is assembled. Early acoustic characterization, dielectric strength screening, materials evaluation, endoscope performance assessment, and human factors studies can guide design decisions before the product configuration is stable enough for formal submission testing.

Traditional testing also covers needs that do not fit within ASCA’s current scope. Some device-specific methods, customized fixtures, engineering analyses, clinical safety and effectiveness activities, and international standards pathways require a laboratory engagement outside the ASCA program. In these cases, the quality of the protocol, traceability of measurements, control of test conditions, and completeness of the final report are the factors that determine whether the evidence can withstand technical and regulatory scrutiny.

A well-managed traditional report should clearly identify the device under test, model and serial information, software or firmware version where relevant, test equipment, calibration status, standard edition, acceptance criteria, results, deviations, and conclusion. For manufacturers, this level of detail is not administrative overhead. It is what allows the report to be connected to the design history file, risk management file, and final submission narrative.

Documentation and Timing Considerations

The decision should be made before protocol approval, not after final testing. Changing from a traditional report to an ASCA report late in the program may require confirmation that the exact method, standard edition, equipment, sample selection, and report structure satisfy ASCA requirements. A retest may be necessary if the original work cannot support the requested report format.

Manufacturers should also control the relationship between the test article and the commercial configuration. A report is less useful when it identifies a prototype that differs materially from the device described in the 510(k), De Novo request, or premarket approval submission. Hardware revisions, material changes, software updates, accessories, transducers, power supplies, and operating modes should be assessed for their impact on previously completed testing.

Clear communication between the manufacturer and laboratory is therefore critical. The laboratory needs the intended use, device classification context, selected standards, applicable accessories, operating modes, and planned regulatory use of the data. The manufacturer needs an early determination of testing scope, sample requirements, expected deliverables, deviations management, and realistic scheduling.

Sigma Scientific Services applies this scope-focused approach to medical device safety and performance testing, helping teams identify testing that aligns with applicable standards and the intended regulatory pathway.

Selecting the Right Path for the Device Program

The practical question is not whether ASCA testing versus traditional testing is better in the abstract. The question is which approach produces defensible evidence for the specific device, standard, and submission objective.

Start with the regulatory claim the manufacturer expects to make. If the submission will include a declaration of conformity to an eligible FDA-recognized consensus standard, assess ASCA availability at the same time the standard is selected. If the project includes specialized performance characterization, nonstandard methods, early design verification, or standards outside ASCA scope, plan traditional testing with the same level of rigor and documentation control.

The most effective programs use the testing pathway as part of design and regulatory planning, rather than treating it as a final procurement task. When the laboratory scope, standard edition, test article, and submission strategy are aligned before samples arrive, the resulting evidence is more likely to support a timely and technically credible review.